NCT02508805View on ClinicalTrials.gov

Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

November 30, 2015

Conditions
Vertebrogenic Radiculopathy L5, S1
Interventions
DRUG

Neuromultivit

DRUG

Voltaren

DRUG

Sirdalud

Trial Locations (1)

420021

State Autonomous Institution Republican Clinical Centre of Neurology, Kazan'

All Listed Sponsors
collaborator

Valeant Russia, LLC

UNKNOWN

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT02508805 - Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy | Biotech Hunter | Biotech Hunter